Extrapyramidal side-effects and dopamine D_2/3 receptor binding in substantia nigra

References

• Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993;54:133–9.
   PubMed Web of Science ®Google Scholar
• Miller CH, Mohr F, Umbricht D, Woerner M, Fleischhacker WW, Lieberman JA. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics. J Clin Psychiatry 1998;59:69–75.
   PubMed Web of Science ®Google Scholar
• Wirshing WC. Movement disorders associated with neuroleptic treatment. J Clin Psychiatry 2001;62 Suppl 21:15–8.
   PubMedGoogle Scholar
• Casey DE. Pathopsysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 2004;65 Suppl 9:25–8.
   PubMed Web of Science ®Google Scholar
• Seeman P, Tallerico T. Antipsychotic drugs elicit little or no Parkinsonism bind more loosely than dopamine to brain D2 receptors, yet occupy high levels of these receptors. Mol Psychiatry 1998;3:123–34.
   PubMed Web of Science ®Google Scholar
• Kapur S, Seeman P. Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 2001;158:360–9.
   PubMed Web of Science ®Google Scholar
• Abi-Dargham A, Laruelle M. Mechanism of action of second generation antipsychotic drugs in schizophrenia: Insight from brain imaging studies. Eur Psychiatry 2005;20:15–27.
   PubMed Web of Science ®Google Scholar
• Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992;49: 538–44.
   PubMed Web of Science ®Google Scholar
• Scherer J, Tatsch K, Schwarz J, Oertel WH, Konjarczyk M, Albus M. D2-dopamine receptor occupancy differs between patients with and without extrapyramidal side effects. Acta Psychiatr Scand 1994;90:266–8.
   PubMedGoogle Scholar
• Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: A PET study. Life Sci 1995;57: PL103–7.
   PubMed Web of Science ®Google Scholar
• Kapur S, Zipursky R, Jones C, Remington G, Houle S. Relationship between dopamine D2 occupancy, clinical response, and side effects: A double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514–20.
   PubMed Web of Science ®Google Scholar
• Agid O, Mamo D, Ginovart N, Vitcu I, Wilson AA, Zipursky RB, . Striatal vs. extrastriatal dopamine D2 receptors in antipsychotic response—A double-blind PET study in schizophrenia. Neuropsychopharmacology 2007;32:1209–15.
   PubMed Web of Science ®Google Scholar
• Schröder J, Silvestri S, Bubeck B, Karr M, Demisch S, Scherrer S, . D2 dopamine receptor up-regulation, treatment response, neurological soft signs, and extrapyramidal side effects in schizophrenia: A follow-up study with 123I-iodobenzamide single photon emission computed tomography in the drug-naïve state and after neuroleptic treatment. Biol Psychiatry 1998;43:660–5.
   PubMed Web of Science ®Google Scholar
• Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, . Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study. Psychopharmacology 2000;152:174–80.
   PubMed Web of Science ®Google Scholar
• Double KL, Crocker AD. Dopamine receptors in the substantia nigra are involved in the regulation of muscle tone. Proc Natl Acad Sci USA 1995;92:1669–73.
   PubMedGoogle Scholar
• Crocker AD, Hemsley KM. An animal model of extrastriatal side effects induced by antipsychotic drugs: Relationship with D2 dopamine receptor occupancy. Prog Neuropsychopharmacol Biol Psychiatry 2001;25:573–90.
   PubMedGoogle Scholar
• Meador-Woodruff JH, Damask SP, Watson SJ Jr. Differential expression of autoreceptors in the ascending dopamine systems of the human brain. Proc Natl Acad Sci USA 1994;91:8297–301.
   PubMedGoogle Scholar
• Hurd YL, Suzuki M, Sedvall GC. D1 and D2 dopamine receptor mRNA expression in whole hemisphere sections of the human brain. J Chem Neuroanat 2001;22:127–137.
   PubMed Web of Science ®Google Scholar
• Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, . Occupancy of striatal and extrastriatal dopamine d(2)/d(3) receptors by olanzapine and haloperidol. Neuropsychopharmacology 2005;12:2283–9.
   Google Scholar
• Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, . Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006;31:1991–2001.
   PubMed Web of Science ®Google Scholar
• Tuppurainen H, Kuikka JT, ViinamÄki H, Husso M, Tiihonen J. Dopamine D2/3 receptor binding potential and occupancy in midbrain and temporal cortex by haloperidol, olanzapine and clozapine. Psychiatry Clin Neurosci 2009;63:529–37.
   PubMedGoogle Scholar
• Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970;212:11–9.
   PubMedGoogle Scholar
• Kuikka JT, Åkerman KK, Hiltunen J, Bergström KA, RÄsÄnen P, Vanninen E, . Striatal and extrastriatal imaging of dopamine D2 receptors in the living human brain with [123I]epidepride single-photon emission tomography. Eur J Nucl Med 1997;24:483–7.
   PubMedGoogle Scholar
• Hemsley KM, Crocker AD. The effect of an irreversible dopamine receptor antagonist, N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ), on the regulation of muscle tone in the rat: The role of the substantia nigra. Neurosci Lett 1998;251:77–80.
   PubMedGoogle Scholar
• Hemsley KM, Crocker AD. Raclopride and chlorpromazine, but not clozapine, increase muscle rigidity in the rat: Relationship with D2 dopamine receptor occupancy. Neuropsychopharmacology 1999;21:101–9.
   PubMedGoogle Scholar
• Chiodo LA, Bunney BS. Typical and atypical neuroleptics: Differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. J Neurosci 1983;3:1607–19.
   PubMed Web of Science ®Google Scholar
• Carlsson A, Lindqvist M. Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 1963;20:140–4.
   PubMedGoogle Scholar
• Pucak ML, Grace AA. Evidence that systemically administered dopamine antagonists activate dopamine neuron fring primarily by blockade of somatodendritic auroreceptors. J Pharmacol Exp Ther 1994;271:1181–92.
   PubMedGoogle Scholar
• Grace AA, Bunney BS. Induction of depolarization block in midbrain dopamine neurons by repeated administration of haloperidol: Analysis using in vivo intracellular recording. J Pharmacol Exp Ther 1986;238:1092–100.
   PubMed Web of Science ®Google Scholar
• Grace AA. The depolarization block hypothesis of neuroleptic action: Implications for the etiology and treatment of schizophrenia. J Neural Transm Suppl 1992;36:91–131.
   PubMedGoogle Scholar
• Gründer G, Vernaleken I, Müller MJ, Davids E, Heydari N, Buchholz HG, . Subchronic haloperidol downregulates dopamine synthesis capacity in the brain of schizophrenic patients in vivo. Neuropsychopharmacology 2003;28:787–94.
   PubMedGoogle Scholar
• White FJ, Wang RY. Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 1983;221:1054–7.
   PubMed Web of Science ®Google Scholar
• Timmerman W, Heijmen M, Westerink BHC, Bruggeman R, den Boer JA. Effects of acute and chronic administration of olanzapine in comparison to clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons in the rat brain. Psychopharmacology 1999;144:286–94.
   PubMed Web of Science ®Google Scholar
• Tarsy D, Baldessarini RJ, Tarazi FI. Effects of newer antipsychotics on Extrapyramidal function. CNS Drugs 2002;16:23–45.
   PubMed Web of Science ®Google Scholar
• Weiden PJ. EPS profles: The atypical antipsychotics are not the same. J Psychiatr Pract 2007;13:13–24.
   PubMedGoogle Scholar
• Vernaleken I, Siessmeier T, Buchholz HG, HÄrtter S, Hiemke C, Stoeter P, . High striatal occupancy of D2-like dopamine receptors by amisulpiride in the brain of patients with schizophrenia. Int J Neuropsychopharmacol 2004;7:421–30.
   PubMedGoogle Scholar
• Seeman P, Bzowej NH, Guan HC, Bergeron C, Becker LE, Reynolds GP, . Human brain dopamine receptors in children and aging adults. Synapse 1987;1:399–404.
   PubMed Web of Science ®Google Scholar
• Ichise M, Ballinger JR, Tanaka F, Moscovitch M, St. George-Hyslop PH, Raphael D, . Age-related changes in D2 receptor binding with iodine-123–iodobenzofuran SPECT. J Nucl Med 1998;39:1511–8.
   PubMedGoogle Scholar
• Kaasinen V, Vilkman H, Hietala J, NÅgren K, Helenius H, Olsson H, . Age–related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. Neurobiol Aging 2000;21:683–8.
   PubMed Web of Science ®Google Scholar
• Cabello CR, Thune JJ, Pakkenberg H, Pakkenberg B. Ageing of substantia nigra in humans: Cell loss may be compensated by hypertrophy. Neuropathol Appl Neurobiol 2002;28:283–91.
   PubMedGoogle Scholar
• Wong DF, Pearlson GD, Tune LE, Young LT, Melzer CC, Dannals RF, . Quantification of neuroreceptors in the living human brain: IV. Effect of aging and elevations of D2-like receptors in schizophrenia and bipolar illness. J Cereb Blood Flow Metab 1997;3:331–41.
   Google Scholar
• Talvik M, Nordström AL, Olsson H, Halldin C, Farde L. Decreased thalamic D2/D3 receptor binding in drug-naïve patients with schizophrenia: A PET study with [11C]FLB 457. Int J Neuropsychopharmacol 2003;6:361–70.
   PubMed Web of Science ®Google Scholar
• Volkow N, Gur RC, Wang GJ, Fowler JS, Moberg PJ, Ding YS, . Association between decline in brain dopamine activity with age and cognitive and motor impairment in healthy individuals. Am J Psychiatry 1998;155:344–49.
   PubMed Web of Science ®Google Scholar
• Pinborg LH, Videbaek C, Knudsen GM, Swahn CG, Halldin C, Friberg L, . Dopamine D(2) quantification in extrastriatal brain regions using [(123)I]epidepride with bolus/infusion. Synapse 2000;36:322–9.
   PubMed Web of Science ®Google Scholar
• Hall H, Farde L, Halldin C, Hurd YL, Pauli S, Sedvall G. Autoradiographic localization of extrastriatal D2-dopamine receptors in the human brain using [125I]epidepride. Synapse 1996;23:115–23.
   PubMed Web of Science ®Google Scholar
• Gurevich EV, Joyce JN. Distribution of dopamine D3 receptor expressing neurons in the human forebrain: Comparison with D2 receptor expressing neurons. Neuropsychopharmacology 1999;20:60–80.
   PubMed Web of Science ®Google Scholar
• Okubo Y, Olsson H, Ito H, Lofti M, Suhara T, Halldin C, . PET mapping of extrastriatal D2-like dopamine receptors in the human brain using an anatomic standardization technique and [11C]FLB 457. NeuroImage 1999;10:666–74.
   PubMedGoogle Scholar
• Tuppurainen H, Kuikka JT, Laakso MP, ViinamÄki H, Husso M, Tiihonen J. Midbrain dopamine D2/3 receptor binding in schizophrenia. Eur Arch Psychiatry Clin Neurosci 2006;256:382–7.
   PubMedGoogle Scholar
• Janno S, Holi MM, Tuisku K, Wahlbeck K. Validity of Simpson-Angus Scale (SAS) in a naturalistic schizophrenic population. BMC Neurology 2005;5:5.
   PubMed Web of Science ®Google Scholar
• Kessler RM, Ellis JR, Eden M. Analysis of emission tomographic scan data: Limitations imposed by resolution and background. J Comput Assist Tomogr 1984;8:514–22.
   PubMed Web of Science ®Google Scholar
• Fox PT, Mintun MA, Reiman EM, Raichle ME. Enhanced detection of focal brain responses using intersubject averaging and change-distribution analysis of subtracted PET images. J Cereb Blood Flow Metab 1988;8:642–53.
   PubMed Web of Science ®Google Scholar
• Ichise M, Fujita M, Seibyl JP, Verhoeff NP, Baldwin RM, Zoghbi SS, . Graphical analysis and simplified quantification of striatal and extrastriatal dopamine D2 receptor binding with [123I]epidepride SPECT. J Nucl Med. 1999;40:1902–12.
   PubMedGoogle Scholar
• Pinborg LH, Videbaek C, Ziebell M, Mackeprang T, Friberg L, Rasmussen H, . [123I]Epidepride binding to cerebellar dopamine D2/D3 receptors is displaceable: Implications for the use of cerebellum as a reference region. NeuroImage 2007;34:1450–3.
   PubMed Web of Science ®Google Scholar